AUTOANTIBODY STATUS IS NOT ASSOCIATED WITH EARLY TREATMENT RESPONSE TO FIRST-LINE METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

被引：0
|
作者：
Dekkerst, J. S. [1 ]
Bergstra, S. A. [1 ]
Chopra, A. [2 ]
Tikly, M. [3 ]
Fonseca, J. E. [4 ]
Salomon-Escoto, K. [5 ]
Huizinga, T. [6 ]
van der Woude, D. [6 ]
机构：
[1] LUMC, Rheumatol, Leiden, Netherlands
[2] Ctr Rheumat Dis, Rheumatol, Pune, Maharashtra, India
[3] Univ Witwatersrand, Div Rheumatol, Johannesburg, South Africa
[4] Lisbon Acad Med Ctr, Rheumatol Res Unit, Lisbon, Portugal
[5] UMass Mem Med Ctr, Dept Rheumatol, Worcester, MA USA
[6] LUMC, Dept Rheumatol, Leiden, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0643
引用
收藏
页码：843 / 844
页数：2
相关论文
共 50 条
  • [1] Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis
    Dekkers, Jacqueline S.
    Bergstra, Sytske Anne
    Chopra, Arvind
    Tikly, Mohammed
    Fonseca, Joao Eurico
    Salomon-Escoto, Karen
    Huizinga, Tom W. J.
    van der Woude, Diane
    RHEUMATOLOGY, 2019, 58 (01) : 149 - 153
  • [2] Should methotrexate be a first-line treatment for rheumatoid arthritis?
    Wilke, WS
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1999, 66 (04) : 207 - 208
  • [3] THE IMPORTANCE OF TREATMENT STRATEGY FOR THE OUTCOME OF EARLY RHEUMATOID ARTHRITIS PATIENTS NOT RESPONDERS TO THE FIRST LINE THERAPY WITH METHOTREXATE
    Fedele, Anna Laura
    Tolusso, Dario Bruno Barbara
    Petricca, Luca
    Ferraccioli, Gianfranco
    Gremese, Elisa
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1578 - 1579
  • [4] IS SIDE EFFECTS AND TREATMENT RESPONSE TO METHOTREXATE ASSOCIATED TO COMORBIDITY IN EARLY RHEUMATOID ARTHRITIS
    Pedersen, K. L.
    Hallas, J.
    Hansen, I. M. J.
    Ahlquist, P.
    Ellingsens, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 592 - 592
  • [5] First-line Therapy with Etanercept for Patients with Early-Stage Rheumatoid Arthritis
    Lorenz, Judith
    AKTUELLE RHEUMATOLOGIE, 2020, 45 (04)
  • [6] Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry
    Manfredi, Andreina
    Sebastiani, Marco
    Iannone, Florenzo
    Gremese, Elisa
    Bortoluzzi, Alessandra
    Favalli, Ennio Giulio
    Roberto, Gorla
    Salaffi, Fausto
    Fusaro, Enrico
    Foti, Rosario
    Cantarini, Luca
    Caporali, Roberto
    Cauli, Alberto
    Alivernini, Stefano
    Cantatore, FrancescoPaolo
    Carletto, Antonio
    Conti, Fabrizio
    D'Angelo, Salvatore
    Epis, Oscar
    Ramonda, Roberta
    Marchesoni, Antonio
    Ferraccioli, Gianfranco
    Lapadula, Giovanni
    INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 (04) : 271 - 276
  • [7] Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
    Kolan, Shrikant S.
    Li, Gaoyang
    Grimolizzi, Franco
    Sexton, Joe
    Goll, Guro
    Kvien, Tore K.
    Sundlisaeter, Nina Paulshus
    Zucknick, Manuela
    Lillegraven, Siri
    Haavardsholm, Espen A. A.
    Skalhegg, Bjorn Steen
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
    Hayashi S.
    Suzuki K.
    Yoshimoto K.
    Takeshita M.
    Kurasawa T.
    Yamaoka K.
    Takeuchi T.
    Rheumatology and Therapy, 2016, 3 (1) : 155 - 166
  • [9] Comorbidities and chance of remission in patients with early rheumatoid arthritis receiving methotrexate as first-line therapy: a Swedish observational nationwide study
    Tidblad, Liselotte
    Westerlind, Helga
    Delcoigne, Benedicte
    Askling, Johan
    Saevarsdottir, Saedis
    RMD OPEN, 2023, 9 (04):
  • [10] DO COMORBIDITIES INCREASE THE RISK OF FAILURE TO REACH REMISSION IN EARLY RHEUMATOID ARTHRITIS PATIENTS RECEIVING METHOTREXATE AS FIRST-LINE THERAPY?
    Tidblad, L.
    Westerlind, H.
    Delcoigne, B.
    Askling, J.
    Saevarsdottir, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 222 - 223
12345